Research to be presented on Orencia, deucravacitinib and pipeline assets highlights breadth of data and focus on transforming treatment paradigms for people living with rheumatic diseases Bristol Myers Squibb today announced data from 29 company-sponsored presentations across Orencia, deucravacitinib and pipeline assets will be presented at the American College of Rheumatology Convergence 2021, taking place .
Share this article
Share this article
EXTON, Pa., Feb. 10, 2021 /PRNewswire/ Despite the potential for setbacks brought forth by the COVID-19 pandemic, Amgen recently reported strong year-over-year growth for their newly acquired psoriasis (PSO) and psoriatic arthritis (PsA) agent, Otezla.
1 In late 2019, the brand was sold to Amgen in order to clear the path for Bristol-Myers Squibb s acquisition of Celgene, considering future regulatory conflicts with BMS pipeline psoriasis drug, deucravacitinib, an oral TYK2 inhibitor anticipated to be in direct competition with Otezla.
Amgen s purchase of Otezla strengthens the company s long-standing immunology portfolio, including TNF inhibitor, Enbrel, which has been approved in RA for over two decades and also holds a dual PSO/PsA indication. However, according to ongoing feedback collected from US dermatologists and rheumatologists included in Spherix s